- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Usher Syndrome.
Displaying page 1 of 1.
EudraCT Number: 2022-001092-14 | Sponsor Protocol Number: TIGEM5_USH | Start Date*: 2023-10-12 | ||||||||||||||||
Sponsor Name:FONDAZIONE TELETHON | ||||||||||||||||||
Full Title: A phase I/II open label, dose escalation study of sub-retinal administration of a “mixture of two adeno-associated viral vectors of serotype 8 containing the 5 ´- half sequence of the human MYO7A ... | ||||||||||||||||||
Medical condition: Usher syndrome (USH) is characterized by the association of sensorineural hearing loss, Retinitis Pigmentosa (RP), and, in some cases, vestibular dysfunction. It is the most frequent cause of deaf-... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002574-31 | Sponsor Protocol Number: US1/001/10(TDU13600) | Start Date*: 2013-10-25 | ||||||||||||||||
Sponsor Name:sanofi-aventis recherche & développement | ||||||||||||||||||
Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B | ||||||||||||||||||
Medical condition: Retinitis Pigmentosa, associated with Ushers Syndrome Type 1B. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002433-38 | Sponsor Protocol Number: PQ-421a-001 | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:ProQR Therapeutics | |||||||||||||
Full Title: A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002728-19 | Sponsor Protocol Number: PQ-421a-004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t... | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NO (Prematurely Ended) DK (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002729-74 | Sponsor Protocol Number: PQ-421a-003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t... | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NO (Completed) DK (Completed) NL (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000385-22 | Sponsor Protocol Number: RF-2010-2318561 | Start Date*: 2014-10-07 | ||||||||||||||||
Sponsor Name:Ospedale San Raffaele di Milano | ||||||||||||||||||
Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial. | ||||||||||||||||||
Medical condition: Retinitis pigmentosa with cystoid macular edema | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.